Exchange: NASDAQ·Updated 09:51 AM EDT

RZLT News

News
all
press releases
This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for several names.read more...
Benzinga
This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for several names.read more...
Benzinga
More News
FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints
Rezolute (NASDAQ: RZLT) shares surged after the FDA recommended a pre-BLA meeting for its congenital hyperinsulinism drug, ersodetug.read more...
Benzinga
Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’
The U.S. Food and Drug Administration recommended that the company request a Type B pre-BLA meeting for Ersodetug in congenital hyperinsulinism
Stocktwits
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.
Zacks
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study
Rezolute says 6 of 8 patients met the primary endpoint in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism.read more...
Benzinga
Rezolute (RZLT) to Release Quarterly Earnings on Tuesday
Rezolute (NASDAQ:RZLT) will be releasing its Q3 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at...
MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Short Interest Down 21.2% in March
Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 13,353,457 shares, a decline of 21.2...
MarketBeat
What is HC Wainwright's Estimate for Rezolute Q1 Earnings?
Rezolute, Inc. (NASDAQ:RZLT - Free Report) - HC Wainwright cut their Q1 2027 EPS estimates for Rezolute in a research report issued on Monday, March 30th. HC Wainwright analyst D. Tsao now...
MarketBeat
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.
Zacks
Rezolute (NASDAQ:RZLT) Stock Rating Upgraded by Wedbush
Wedbush upgraded Rezolute from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $2.00 to $5.00 in a report on Wednesday...
MarketBeat

Advertisement|Remove ads.